UC San Diego and a growing coalition of regional institutions are making clinical research more accessible and more impactful across Southern California.
Cylembio (imsapepimut and etimupepimut, adjuvanted), an off-the-shelf therapeutic cancer vaccine, plus pembrolizumab narrowly missed on its primary endpoint of progression free survival for patients with unresectable or metastatic melanoma, according to phase III trial results.
